Intensity Therapeutics INTS
NASDAQ INTS
$3.27 -0.01 (-0.37%)
As of: Oct 21, 2026 · 12:09 PM EDT

Intensity Therapeutics (INTS) Preferred Stock Liabilities (2022)

Updated

Intensity Therapeutics (INTS) posted Preferred Stock Liabilities of $10 million for Q4 2022.

Analysis

Intensity Therapeutics (INTS) Preferred Stock Liabilities (2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,134.96 Bn 1,103.55 Bn 19.71 Bn -
2 Johnson & Johnson 616.51 Bn 535.04 Bn 17.26 Bn -
3 AbbVie 501.10 Bn 474.21 Bn 12.70 Bn -
4 Merck 367.09 Bn 321.47 Bn 12.21 Bn -
5 Novartis Ag 298.10 Bn 262.09 Bn 11.24 Bn -
6 Astrazeneca 261.72 Bn 235.40 Bn 12.86 Bn -
7 Amgen 235.73 Bn 191.13 Bn 7.24 Bn -
8 Gilead Sciences 190.64 Bn 164.84 Bn 6.22 Bn -
9 Pfizer 169.63 Bn 116.28 Bn 10.94 Bn -
10 Intensity Therapeutics 8.85 Mn -29.92 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 10.00 Mn
API Access

Intensity Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=INTS&period=max&api_key=YOUR_API_KEY